𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Somatic Hypermutations in the VHSegment of Immunoglobulin Genes of CDS-positive Diffuse Large B-Cell Lymphomas

✍ Scribed by Kume, Masaaki ;Suzuki, Ritsuro ;Yatabe, Yasushi ;Kagami, Yoshitoyo ;Miura, Ikuo ;Miura, Akira B. ;Morishima, Yasuo ;Nakamura, Shigeo ;Seto, Masao

Book ID
108581365
Publisher
Wiley (Blackwell Publishing)
Year
1997
Tongue
English
Weight
412 KB
Volume
88
Category
Article
ISSN
0910-5050

No coin nor oath required. For personal study only.

πŸ“œ SIMILAR VOLUMES

The therapeutic effect of rituximab on C
The therapeutic effect of rituximab on CD5-positive and CD5-negative diffuse large B-cell lymphoma
✍ Rie Hyo; Naoto Tomita; Kengo Takeuchi; Tomohiro Aoshima; Atsuko Fujita; Hideyuki πŸ“‚ Article πŸ“… 2009 πŸ› John Wiley and Sons 🌐 English βš– 111 KB

## Abstract The prognosis of diffuse large B‐cell lymphoma (DLBCL) has improved markedly in recent years of rituximab era. The prognosis of __de novo__ CD5‐positive DLBCL is reported to be poor, but the effect of rituximab on this type of lymphoma remains unclear. To investigate the effect of ritux

Hypermutation of the MYC gene in diffuse
Hypermutation of the MYC gene in diffuse large cell lymphomas with translocations involving band 8q24
✍ John F. Bradley; Paul G. Rothberg; Marc Ladanyl; R. S. K. Chaganti πŸ“‚ Article πŸ“… 1993 πŸ› John Wiley and Sons 🌐 English βš– 303 KB πŸ‘ 1 views

The sequence of the exon I lintron I boundary region of the MYC gene was determined in two diffuse large cell lymphomas (DLCL), one with t(8; 14) (q24q32) and the other with t(8;22) (q24;q I I). Both tumors had multiple mutations in this region. Also, both tumors had mutations in the protein binding

Identification of genes putatively invol
Identification of genes putatively involved in the pathogenesis of diffuse large B-cell lymphomas by integrative genomics
✍ Joost J. Oudejans; Wessel N. van Wieringen; Serge J. Smeets; Marianne Tijssen; S πŸ“‚ Article πŸ“… 2009 πŸ› John Wiley and Sons 🌐 English βš– 235 KB

## Abstract Diffuse large B‐cell lymphomas (DLBCL) are highly heterogeneous with regard to clinical presentation and outcome. DLBCL copy number aberrations have been identified previously, of which the deletion at 6q21‐24 was significantly associated with a highly favorable clinical response to che